Revolutionizing Weight-Loss Medications: The Discovery of a New Enzyme
Scientists at the University of Utah have made a groundbreaking discovery. They have identified a natural enzyme, PapB, that could potentially revolutionize weight-loss medications like Ozempic. This enzyme could enhance the effectiveness of these medications and prolong their impact within the body. PapB has the unique ability to transform fragile drug molecules into durable ring-shaped structures through a process known as macrocyclization.
The research, published on April 28, reveals that PapB can effectively “lock” therapeutic peptides. These protein-like building blocks are integral to drugs like semaglutide, the active ingredient in Ozempic. By locking these peptides into compact rings, they become more stable and resistant to breakdown. “By using this enzymatic method to tie off the ends, we are essentially hiding the peptide from some of the most common proteases in the body—which are what breaks down peptides,” elucidated Karsten Eastman, research associate and CEO of Sethera Therapeutics.
This discovery addresses a significant challenge with peptide-based medications. The body’s natural enzymes swiftly break these medications down, which limits their effectiveness. However, ring-shaped peptides offer multiple advantages. They remain active for a longer period, interact more effectively with biological targets, and could potentially reduce the frequency of injections required for treatments.
The research team successfully tested PapB on three different GLP-1-like peptides. Each peptide was converted from an open chain into a ring structure. This enzymatic approach is simpler and more precise than traditional chemical methods, which can often be too harsh for delicate peptide drugs. In recognition of this breakthrough, the University of Utah’s Technology Licensing Office named the researchers as the 2025 Founders of the Year for developing the PolyMacrocyclic Peptide Discovery Platform.
Source: Science Daily